

**Role of finasteride in improvement of quality of life in male pattern hair loss****Mani Bharti<sup>1</sup>, Sunita Singh<sup>2</sup>, Anshumali<sup>3</sup>, Anisha Prasad<sup>4\*</sup>, Meenakshi Maurya<sup>5</sup>, Yogesh Kumar Goyal<sup>6</sup>, Sukanta Sen<sup>7</sup>**

<sup>1</sup>Senior Resident, Department of Pharmacology, North Delhi Municipal Corporation, Medical College & Hindu Rao Hospital, Malka Ganj, Delhi 110007, New Delhi, India

<sup>2</sup>Professor & Head, Department of Pharmacology, North Delhi Municipal Corporation, Medical College & Hindu Rao Hospital, Malka Ganj, Delhi 110007, New Delhi, India

<sup>3</sup>Associate Professor, Department of Anesthesiology, North Delhi Municipal Corporation, Medical College & Hindu Rao Hospital, Malka Ganj, Delhi 110007, New Delhi, India

<sup>4</sup>Associate Professor, Department of Pharmacology, North Delhi Municipal Corporation, Medical College & Hindu Rao Hospital, Malka Ganj, Delhi 110007, New Delhi, India

<sup>5</sup>Associate Professor, Department of Pharmacology, S.N. Medical College, Moti Katra, Agra 282002, Uttar Pradesh, India

<sup>6</sup>Professor, Department of Pharmacology, S.N. Medical College, Moti Katra, Agra 282002, Uttar Pradesh, India

<sup>7</sup>Professor & Head, Department of Pharmacology, Department of Pharmacology, ICARE Institute of Medical Sciences and Research, Haldia, Purba Medinipur 721645, West Bengal, India

Received: 26-04-2021 / Revised: 13-06-2021 / Accepted: 16-07-2021

**Abstract**

**Background:** Androgenic alopecia (AGA) may be a common hair loss disorder with genetic predisposition seen usually in men. Despite the fact that the condition is harmless, non-life threatening however it causes a big psychological stress and affects the individual's overall quality of life (QoL). **Objectives:** This study was done to assess the QoL in patients' treatment with 1 mg oral finasteride with the help of dermatological Life Quality Index (DLQI) form. **Methods:** This study was conducted within the Department of Clinical pharmacology and therapeutics with the collaboration of dermatology department at S. N. Medical College and Associated Hospital, Agra (U.P.), once taking approval from the institutional ethical committee. Seventy male patients were registered during this study, two parameters DLQI score and patient's self-assessment score was taken to assess the quality of life. The DLQI uses ten things concerning symptoms and feelings, daily activities, leisure, work and college, personal relationships, and treatment as dimensions of life, every scored on a 0–3 scale. The full DLQI score equals 0–30; higher scores showing bigger impact on QoL. **Results:** Evaluation was done on 62 patients (due to drop out of 8 patients) aged between 18 to 40 years with a mean age of  $27.90 \pm 5.43$  years, the average duration of hair loss was 23.20 months, maximum number of cases were in grade II that was 20 (32.25%). hair growth was seen in decreasing order as the grade increased improvement decreased. 83.8 % patients (52/62) shown improvement in hair growth, in 2 patients loss of hair (3.2%) was seen, in grade wise analysis maximum improvement was seen in grade II and grade III patients. Average DLQI scores before the treatment was  $8.76 \pm 1.13$  which decrease to  $5.29 \pm 2.08$  after the treatment, this difference was statistically significant ( $p=0.0001$ ). Higher the DLQI means poorer the quality of life.

**Keywords:** Androgenic alopecia, Hair loss, Finasteride, Quality of life (QoL)

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

**Introduction**

Hair represents physical attractiveness and juvenility to men and women, thus hair loss will have important negative impacts on the conceit and quality of life. The foremost common causes of hair loss in men and women are androgenic alopecia (AGA) that could be a genetically determined, age-dependent, progressive hair-loss condition with gender-specific variations in frequency and severity. Male androgenic alopecia (MAGA) also called male pattern hair loss (MPHL), is characterized by the miniaturization of the hair follicles within the frontal and parietal part of scalp [1]. It is the most

common form of alopecia in men with most men in developing some degree of the recession of the hairline during their lifetime, although prevalence may vary, severe MPHL can be seen in around 50% of men beyond age 40 [2,3]. The male hormone androgen plays a vital role within the pathological process of AGA, however heritable heredity is assumed to be the first cause. Within the follicle cells, androgen is reborn into the biologically a lot of active kind, dihydrotestosterone (DHT) a substance, catalyzed by the catalyst 5-alpha reductase enzyme. This binds to steroid hormone receptors within the follicle and therefore the specific bond triggers cellular processes which reduce the duration anagen phase of the hair cycle. For this reason, the hair passes earlier into the telogen phase and falls out. Gradually, over succeeding cycle terminal hair converts into thinner and shorter vellus hair (i.e. the retrograde phase of the cycle) and the hair follicle becomes minute. Hair loss have the negative

\*Correspondence

**Dr. Anisha Prasad**

Associate Professor, Department of Pharmacology, North Delhi Municipal Corporation, Medical College & Hindu Rao Hospital, Malka Ganj, Delhi 110007, New Delhi, India

E-mail: [anisha.prasad@gmail.com](mailto:anisha.prasad@gmail.com)

impact on conceit and quality of life of men thus this study was planned to understand the effect of finasteride on quality of life of an AGA patient.

**Materials & methods**

The present study was conducted within the Department of Clinical Pharmacology and Therapeutics with the collaboration of Dermatology Department at S. N. Medical College and Associated Hospital, Agra (U. P.) after taking approval from the institutional ethical committee. (Letter no: IEC/2017/48).

**Inclusion Criteria:** All male patients of age between 18-40 years who were diagnosed a case of androgenetic alopecia coming in skin OPD, SN Medical College Agra.

**Exclusion Criteria:**

- Patients with alternative reason behind baldness
- Seborrheic eczema or disease of the skin on the scalp
- History of allergic reaction to finasteride

**Study population**

A total of 70 male patients between the ages of 18-40 years in good health, with Androgenetic Alopecia with II to V grade on the modified Norwood Hamilton classification and had given their written informed consent, who complied with all the inclusion and exclusion criteria and able to read and understand the DLQI form in Hindi or English were enrolled into the study sample size. The sample size is calculated with the following formula

$$n = N z^2 P \frac{(1-P)}{d^2(N-1) + z^2 P(1-P)}$$

Where

n= sample size

z= z statistic for a level of confidence,

P= expected prevalence or proportion (50%)

d= precision (in proportion of one; if 3%, = 0.03)

N= Population size

**Study design:** It was an observational, prospective, open-label, study conducted to investigate the result of finasteride on quality of life in AGA patients.

Source of data: Patients enrolled who were diagnosed with androgenetic alopecia in OPD of Dermatology in S.N. Medical College, Agra.

**Duration of study:** One year

**Study assessments:** Two indices were taken to assess the impact of finasteride on quality of life

1. DLQI: The DLQI form consisted of ten queries concerning symptoms and feelings, daily activities, leisure, work and faculty, personal relationships, and treatment as dimensions of life. Every item was scored on a scale of 0–3 points. Scores were supplementary to yield a complete DLQI of 0–30 points; higher scores indicated poorer the patient’s QoL.
2. Patient self assessment- Subjective assessment (the patient’s perception of hair loss severity)

Patients assessed their scalp hair on hair growth assessment scale of 0-4

0: (No improvement); 1: (1- twenty fifth improvement); 2: (26-50% improvement); 3: (51 -75% improvement); and 4: (76 -100% improvement)

All the patients were evaluated and details like age of onset, length of sickness, severity grading of AGA was done and details recorded during a structured proforma.

**Results**

Although the study was started with 70 patients but 8 patients dropout the study due to some unknown reasons so evaluation was done on 62 patients aged between 18 to 40 years with a mean age of 27.90 ± 5.43 years; the average duration of hair loss was 23.20 months, maximum number of cases were in grade II that was 20 (32.25%). hair growth was seen in decreasing order as the grade increased improvement decreased. About 83.8% patients (52/62) shown improvement in hair growth, in 2 patients loss of hair (3.2%) was seen, in grade wise analysis maximum improvement was seen in grade II and grade III patients. Average DLQI scores before the treatment was 8.76 ±1.13 which decrease to 5.29 ±2.08 after the treatment, this difference was statistically significant (p=.0001) higher the DLQI means poorer the quality of life.

**Table 1: DLQI before and after treatment**

	DLQI Before treatment	DLQI After treatment
<b>Mean</b>	8.76	5.29
<b>SD</b>	±1.13	±2.08
<b>p value</b>	0.00001	

Table 1 illustrates the dermatology life quality index score change, before and after the treatment in it was 8.76 ±1.13 before treatment 5.29± 2.08 after treatment. This was also statistically significant (p=0.0001).The similar result also find in Yamazaki, Masashi et al study “oral finasteride improved the quality of life of androgenetic alopecia patients “they also said finasteride improve the quality of life [4]. Other study by Xiao-Sheng (2013) et al also finds the similar result [5].

**Table 2: Patient self- assessment score change from the baseline to subsequent follow up**

Before t/t	After treatment		
	3 (M)	6 (M)	9 (M)
0	0.85	2.00	2.16
0	±0.72	±2.87	±1.27
	2.29	8.61	7.83
	0.02	.00001	.00001

Table 2 illustrates patient self assessment score change from the baseline to subsequent follow up. Patient self- assessment score change from the baseline to 3-month was 0.85 ±0.72 and baseline to 6 & 9 months it was 2.00±2.87 and 2.16±.1.27 respectively .that was statistically significant (P value =0.00001).

**Table 3: Analysis of patient’s self-assessment after treatment**

Patient self-assessment score	Patients (n)	Patients (%)
0	10	16.12
1	5	8
2	22	35.48
3	15	24.19
4	10	16.12

Table 3 illustrates analysis of patient's self-assessment score after the treatment. About 83.88% patients were satisfied with the treatment 16.12% patients were not satisfied with the treatment. Out of 83.88% patients 43% patients were satisfied with the mild increase in hair growth and 40% patients were satisfied with the moderate increase in hair growth. About 16.12% patients showed a moderate increase in hair growth.

### Discussion

Hair incorporates a big role inside the general look of the person that has numerous social and social implications. Inside the cognitive content context, hair has been given innumerable importance and extensive hair has symbolized vitality, health, and virility, whereas loss or removal of hair will connote subjugation, loss of individuality, impotency, and/or impairment. Hair quality, Associate in good look could also be an indicator of attractiveness for many folks, and visual hair loss will have a heavy negative impact. Hair loss considerably impacts associate in nursing individual's character and studies indicate that patients with the hair loss could have considerably shrunken quality of life. The standard of life is outlined as a result of the subjective perception of the impact on the health standing, and on the physical, psychological, and social functioning and well-being of the patients. Quality of life assessments help, in clinical practice, clinicians to make judgments about which aspects of daily life are most affected by the disease. In our study, the mean DLQI score was  $8.76 \pm 1.13$  which are comparable to the score of 6.3 reported by Zhang et al in 178 patients of AGA [6]. Williamson et al also reported a mean score of  $8.3 \pm 5.6$  in 70 patients with alopecia [7]. Our study showed that AGA moderately affected the QoL, including feelings of loss of self-confidence and low self-esteem. In our study, higher scores were recorded for question 2, 3 and 5 inside the form that mirrored the numerous lowered self-worth and self-perception of one's look due to hair loss and hence the impaired social wellbeing of the patients. We have a tendency to ascertained higher DLQI scores in younger patients, patients with long standing hair loss and in higher grades of AGA. These results are in accordance with the findings by Gupta S study [8]. Zhang et al additionally reported higher DLQI scores in younger people, long standing illness and in severe grades of AGA [6]. It has been discovered that men who had additional profound hair loss were additional discontented with their look and were additional involved with their older look than those with borderline hair loss and had lower self-image [9]. This seems to be a result of the strain and importance of physical look and body image in social settings [10]. The present study had several limitations. First, all the patients in our study were recruited in a Dermatology Department and selection bias may, therefore, have affected the results. Also, the study sample was relatively small compared to the total population of alopecia patients in India.

### Conclusion

Patients with AGA have a considerably poor quality of life. Subsequent DLQI score was seen in younger age, long standing hair loss and in severe grades of AGA. Title is said to a lowered self-

worth that in turn finishes up in useful consequences in social group and social interactions. It is vital that physicians contemplate the psychosocial impact of title on totally different aspects of patient's lives. This study indicate that treatment with finasteride improve the hair growth considerably that facilitate in up the quality of life in male patients of androgenous phalacrois.

### References

1. Tsuboi R, Arano O, Nishikawa T, Yamada H, Katsuoka K. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. *J Dermatol.* 2009; 36:437-46.
2. Shapiro J, Oberg N. Hair Loss, and Restoration. CRC Press; 2015.
3. Shin HS, Won CH, Lee SH, Kwon OS, Kim KH, Eun HC. Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial. *Am J Clin Dermatol.* 2007; 8:285-90.
4. Yamazaki M, Miyakura T, Uchiyama M, Hobo A, Irisawa R, Tsuboi R. Oral finasteride improved the quality of life of androgenetic alopecia patients. *J Dermatol.* 2011 Aug;38(8):773-7.
5. Zhuang XS, Zheng YY, Xu JJ, Fan WX. Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients. *Experimental and therapeutic medicine.* 2013 Aug 1; 6(2):542-6.
6. Zhang M, Zhang N. Quality of life assessment in patients with alopecia areata and androgenetic alopecia in the People's Republic of China. *Patient Prefer Adherence.* 2017 Jan 27;11:151-155.
7. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. *J Eur Acad Dermatol Venereol.* 2001 Mar; 15(2):137-9.
8. Gupta S, Goyal I, Mahendra A. Quality of Life Assessment in Patients with Androgenetic Alopecia. *Int J Trichology.* 2019; 11(4):147-152.
9. Han SH, Byun JW, Lee WS, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. *Ann Dermatol.* 2012; 24(3):311-318.
10. Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. *J Am Acad Dermatol.* 1993; 29(4):568-575.

**Conflict of Interest: Nil**

**Source of support: Nil**